Coherus starts asset sale as Wainwright targets Coherus stock at USD 7.00

Coherus Oncology (ISIN US19249H1032) began marketing its remaining legacy biosimilar assets on September 23, 2026, with contingent value rights scheduled for distribution on October 7, 2026, according to Coherus Oncology. The company retained Oppenheimer & Co. to advise the sale process, while H.C. Wainwright maintained a Buy rating and set a USD 7.00 price target on September 21, 2026, as reported by Markets Insider.

Legacy assets move toward sale

The assets include patents, intellectual property, royalties, cell lines and related regulatory materials from the former biosimilars business. The CVRs give eligible shareholders a proportional claim on net cash proceeds from asset sales or licensing fees, rather than promising a fixed payment.

The record date was September 30, 2026, and the distribution is scheduled for October 7, 2026. The company also noted that broker procedures can affect how CVRs are credited, a practical detail that makes the record-date mechanics important for holders.

Revenue growth meets cash pressure

Coherus reported USD 14.31 million of revenue in the second quarter of 2026, up 39.61 percent from USD 10.25 million in the comparable period, according to Markets Insider. The GAAP net loss narrowed to USD 20.63 million from USD 41.34 million, a 50.12 percent improvement on the same comparison basis.

The latest quarterly figures show why the asset sale matters alongside the oncology strategy. Coherus is concentrating commercial efforts on LOQTORZI and developing mid-stage candidates, while legacy assets may provide additional proceeds without being part of the core pipeline.

Analysts see a higher valuation

Zacks lists an average target of USD 7.75 from four short-term analyst reports, with targets ranging from USD 4.00 to USD 10.00. The average target is 568.10 percent above the USD 1.16 last close cited by Zacks, although that comparison uses the Nasdaq price rather than a euro quotation.

Market value and oncology pivot

Coherus had a market capitalization of USD 179.2 million as of October 2, 2026, while its 52-week range was USD 1.09 to USD 2.62. The company is listed on Nasdaq under CHRS and operates in healthcare biotechnology, with LOQTORZI and its clinical pipeline at the center of its stated strategy. A financial calendar listing identifies November 5, 2026, as the next earnings date, according to FinanChill.

More news and analyses on Coherus Oncology stock